Meeder Asset Management Inc Chemo Centryx, Inc. Transaction History

Meeder Asset Management Inc

$1.48 Billion
Q3 2024

Shares

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 09, 2021	SELL	$9.59 - $50.88 $21,980 - $116,616	-2,292 Closed	0 $0
Q1 2021 Apr 28, 2021	BUY	$49.53 - $68.4 $113,522 - $156,772	2,292 New	2,292 $118,000
Q4 2020 Feb 09, 2021	SELL	$47.25 - $65.16 $182,715 - $251,973	-3,867 Closed	0 $0
Q3 2020 Nov 02, 2020	SELL	$46.35 - $61.69 $5,283 - $7,032	-114 Reduced 2.86%	3,867 $212,000
Q2 2020 Aug 11, 2020	BUY	$38.58 - $65.07 $58,178 - $98,125	1,508 Added 60.98%	3,981 $228,000
Q1 2020 May 15, 2020	BUY	$32.73 - $50.78 $65,689 - $101,915	2,007 Added 430.69%	2,473 $100,000
Q4 2019 Feb 13, 2020	BUY	$6.81 - $39.55 $3,173 - $18,430	466 New	466 $18,000
Q3 2019 Oct 17, 2019	SELL	$6.47 - $8.96 $29,393 - $40,705	-4,543 Closed	0 $0
Q2 2019 Aug 05, 2019	SELL	$8.31 - $14.85 $13,570 - $24,250	-1,633 Reduced 26.44%	4,543 $42,000
Q1 2019 Apr 16, 2019	BUY	$10.01 - $13.89 $31,441 - $43,628	3,141 Added 103.49%	6,176 $86,000
Q4 2018 Jan 17, 2019	SELL	$9.15 - $12.26 $759 - $1,017	-83 Reduced 2.66%	3,035 $32,000
Q3 2018 Nov 02, 2018	SELL	$10.49 - $13.72 $37,082 - $48,500	-3,535 Reduced 53.13%	3,118 $0
Q2 2018 Jul 24, 2018	BUY	$10.62 - $13.98 $63,889 - $84,103	6,016 Added 944.43%	6,653 $0
Q1 2018 May 03, 2018	SELL	$5.9 - $14.99 $466 - $1,184	-79 Reduced 11.03%	637 $9,000
Q4 2017 Feb 02, 2018	BUY	$5.53 - $8.42 $3,141 - $4,782	568 Added 383.78%	716 $4,000
Q3 2017 Oct 20, 2017	BUY	$6.5 - $10.69 $962 - $1,582	148	148 $1,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.